hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06328244 id: Community-Based Swallowing briefTitle: Community-Based Swallowing Training for Elderly Individuals: Impact and Benefits overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-06 date: 2024-06 date: 2024-03-25 date: 2024-04-11 name: Copka Sonpashan class: OTHER_GOV briefSummary: The goal of this clinical trial is to explore the impact of systematic simple swallowing training on swallowing function and quality of life in community-dwelling elderly individuals (≥60 year old) with swallowing disorders. It primarily aims to address two key aspects: 1) the prevalence of dysphagia among community-dwelling elderly individuals, and 2) the effects of systematic simple swallowing training on swallowing function and quality of life in community-dwelling elderly individuals with swallowing disorders. All participants are required to undergo a continuous three-week (21 days) systematic simple swallowing training, with weekends off and training conducted only on weekdays. The training will be conducted two sessions per day, lasting 15-30 minutes each. conditions: Dysphagia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 280 type: ESTIMATED name: Simple swallowing training measure: Eating Assessment Tool-10 measure: Time consumed in eating measure: Swallowing-Related Quality of Life Questionnaire sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328231 id: Community elderly dysphagia briefTitle: The Impact of Swallowing Intervention for Elderly Community Dwellers overallStatus: COMPLETED date: 2024-03-25 date: 2024-04-14 date: 2024-04-14 date: 2024-03-25 date: 2024-04-16 name: Copka Sonpashan class: OTHER_GOV briefSummary: The goal of this clinical trial is to explore the impact of systematic simple swallowing training on swallowing function and quality of life in community-dwelling elderly individuals (≥60 year old) with swallowing disorders. It primarily aims to address two key aspects: 1) the prevalence of dysphagia among community-dwelling elderly individuals, and 2) the effects of systematic simple swallowing training on swallowing function and quality of life in community-dwelling elderly individuals with swallowing disorders. All participants are divided into 2 groups. The intervention group is required to undergo a continuous three-week (21 days) systematic simple swallowing training, with weekends off and training conducted only on weekdays. The training will be conducted two sessions per day, lasting 15-20 minutes each. conditions: Dysphagia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 248 type: ACTUAL name: Systematic simple swallowing training measure: Gugging Swallowing Screen measure: Time consumed in eating measure: Swallowing-Related Quality of Life Questionnaire measure: Eating Assessment Tool-10 sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Railway Commu. city: Zhenzhou country: China lat: 32.28034 lon: 119.16999 hasResults: False
nctId: NCT06328218 id: Gymnastics ParkinsonCommunity briefTitle: The Effect of Simple Gymnastics Training for Parkinson's Patients in the Community overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-05 date: 2024-05 date: 2024-03-25 date: 2024-03-25 name: Copka Sonpashan class: OTHER_GOV briefSummary: The goal of this clinical trial is to explore the impact of Simple Gymnastics Training on Limb motor function and mental health in Parkinson's Patients in the Community (≥60 year old) with swallowing disorders. It primarily aims to address two key aspects: 1) the prevalence of Parkinson's Diseases among community-dwelling elderly individuals, and 2) the effects of Simple Gymnastics Training on Limb motor function and mental health in community-dwelling Parkinson's Patients. All patients are required to undergo a continuous three-week (21 days) Simple Gymnastics Training, with weekends off and training conducted only on weekdays. The training will be conducted two sessions per day, lasting 30 minutes each. conditions: Parkinson Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 200 type: ESTIMATED name: Simple Gymnastics Training measure: Unified Parkinson's Disease Rating Scale measure: The Berg Balance Scale measure: Patient Health Questionnaire-9 sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328205 id: Glossopharyngeal Nerve Block briefTitle: Impact of Glossopharyngeal Nerve Block on Swallowing Difficulties Caused by Gastroesophageal Reflux Disease overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-25 date: 2024-03-25 name: Copka Sonpashan class: OTHER_GOV briefSummary: The goal of this clinical trial is to explore Clinical Effect of Glossopharyngeal Nerve Block on Pharyngeal Dysphagia Induced by Gastroesophageal Reflux Disease. The main question it aims to answer is:
• Can Glossopharyngeal Nerve Block improve dysphagia caused by gastroesophageal reflux symptoms on the basis of rehabilitation training? Participants will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Glossopharyngeal Nerve Block once a day additionally. The study lasts 20 days for each participant. Researchers will compare the Rosenbek penetration-aspiration scale, Gastroesophageal Reflux Disease Questionnaire, Pressure pain threshold, to see if the Glossopharyngeal Nerve Block can help improve the symptom. conditions: Dysphagia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Rehabilitation therapy name: Glossopharyngeal Nerve Block name: Lidocaine Hydrochloride name: placebo injection measure: penetration-aspiration scale measure: Gastroesophageal Reflux Disease Questionnaire measure: Pressure pain threshold sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328192 id: active breathing elderly briefTitle: The Impact of Practicing Active Breathing Exercises on Elderly Individuals Living in the Community overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-05 date: 2024-05 date: 2024-03-25 date: 2024-03-25 name: Copka Sonpashan class: OTHER_GOV briefSummary: The goal of this clinical trial is to explore the impact of Active Breathing Exercises on swallowing function and quality of life in community-dwelling elderly individuals (≥60 year old) with swallowing disorders. It primarily aims to address two key aspects: 1) the prevalence of dysphagia among community-dwelling elderly individuals, and 2) the effects of Active Breathing Exercises on swallowing function and quality of life in community-dwelling elderly individuals with swallowing disorders. All participants enrolled are required to undergo a continuous three-week (21 days) Active Breathing Exercises, with weekends off and training conducted only on weekdays. The training will be conducted two sessions per day, lasting 15-30 minutes each. conditions: Dysphagia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 300 type: ESTIMATED name: Active Breathing Exercises measure: Standardized Swallowing Assessment Scale measure: Time consumed in eating measure: Swallowing-Related Quality of Life Questionnaire sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328179 id: KY-2023-058-01 briefTitle: Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. overallStatus: RECRUITING date: 2022-05-24 date: 2027-12-30 date: 2027-12-30 date: 2024-03-25 date: 2024-03-25 name: Huai'an First People's Hospital class: OTHER name: Zhenjiang First People's Hospital name: The First People's Hospital of Changzhou name: The Affiliated Hospital of Xuzhou Medical University briefSummary: This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities.
This study includes the induction and consolidation phases of AML treatment. conditions: Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 34 type: ESTIMATED name: Venetoclax 100 mg d1，200 mg d2，400 mg d3-14； measure: Overall response rate，ORR measure: Overall survival, OS measure: Event free survival, EFS measure: Duration of remission, DOR measure: Adverse event, AE measure: Treatment-related mortality, TRM sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University（Huai'an First People's Hospital） status: RECRUITING city: Huai'an state: Jiangsu zip: 210000 country: China name: Shandong Tao role: CONTACT phone: 15252393900 email: TSD8884@126.com lat: 33.50389 lon: 119.14417 hasResults: False
nctId: NCT06328166 id: rFGF-1 for CTS briefTitle: The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-03-22 date: 2024-12-31 date: 2024-12-31 date: 2024-03-25 date: 2024-03-25 name: Tri-Service General Hospital class: OTHER name: Eusol Biotech Co., Ltd. briefSummary: Carpal tunnel syndrome (CTS) is a common peripheral entrapment mononeuropathy of the upper limb, which results from compression of median nerve at level of wrist. In recent years, regenerative medicine has gradually been applied in the treatment of various degenerative conditions such as bones, muscles, and nerves. Human fibroblast growth factor 1 is a single-chain protein , which has been shown to play a crucial regulatory role in the brain and spinal cord and can facilitate nerve cell differentiation and growth. ES135 is a recombinant human fibroblast growth factor 1 (rhFGF1) which is composed of 135 amino acids with a molecular weight of approximately 15.2 kilodalton. Several studies have shown that significant improvement of Functional Independence Measure, motor and sensory function of spinal cord injury patients after ES135 treatment. One study also revealed the muscle strength have significant improvement in brachial plexus injury patients after ES135 therapy. According to above studies, the investigators hypothesized that ES135 may have benefits to CTS patients. Hence, the purpose of this study aim to demonstrate the therapeutic effects and safety of ES135 for CTS. conditions: Carpal Tunnel Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 28 type: ESTIMATED name: Sono-guided injection with ES135 name: Sono-guided injection with placebo measure: Change from baseline of severity of symptoms and functional status on 1st month, 2nd month, 3rd month,4th month, 6th month after injection. measure: Change from baseline of pain on 1st month, 2nd month, 3rd month,4th month, 6th month after injection. measure: Change from baseline of cross-sectional area of the median nerve on 1st month, 2nd month, 3rd month,4th month, 6th month after injection. measure: Change from baseline of conduction velocity, latency of median nerve on 1st month, 2nd month, 3rd month,4th month, 6th month. sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328153 id: BF2022-101 briefTitle: Efficacy and Mechanism of FSN Treatment for Senile Knee Osteoarthritis overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2026-01-01 date: 2026-03-01 date: 2024-03-25 date: 2024-03-25 name: Guangdong Provincial Hospital of Traditional Chinese Medicine class: OTHER briefSummary: The goal of this clinical trial is to compare FSN with oral Nonsteroidal Antiinflammatory Drugs (NSAIDs) in pain relief and improvement in knee function among elder people, the main questions it aims to answer are:
Researchers will compare FSN and celecoxib to see if FSN has better, or at least equivalent, efficacy than celecoxib, which is commonly used in clinical practice. conditions: Osteoarthritis, Knee studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Fu's Subcutaneous Needling name: Celecoxib measure: Change from Baseline in the visual analogue scale (VAS) (0-100 mm) at the 14th day after receiving treatment. measure: Change from Baseline in the visual analogue scale (VAS) (0-100 mm) at the 7th day, the 28th day and 42th day after the start of treatment. measure: Change from Baseline in The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index at the 7th day, the 14th day, the 28th day and 42th day after the start of treatment. measure: Change from Baseline in the active range of motion (ROM) of the knee at the 7th day,the 14th day,the 28th day and 42th day after the start of treatment. measure: Change from Baseline in the data of the Three-dimensional gait analysis at the 7th day and 14th day after the start of treatment. measure: Change from Baseline in the data of the shear wave elastic imaging technology analysis at the 7th day and 14th day after the start of treatment. measure: Incidence of Treatment-Emergent Adverse Events sex: ALL minimumAge: 60 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328140 id: Skyland 001 briefTitle: Sleep Quality, Cognitive Performance, and Computerized Cognitive Training overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2026-04-14 date: 2026-04-14 date: 2024-03-25 date: 2024-03-25 name: George West Mental Health Foundation d/b/a Skyland Trail class: OTHER name: Sumitomo Pharmaceuticals America briefSummary: Poor sleep quality is common in neuropsychiatric conditions and some of the problems associated with poor sleep at night may be due to medication side effects or reduced efficacy of certain treatments. Poor sleep quality has been implicated in cognitive impairments, with the sleep quality to cognition association so strong that specialized assessments have been developed to examine the subjective association between poor nighttime sleep and daytime cognitive impairment.
Computerized cognitive training (CCT) is a training procedure designed to build cognitive skills, with a goal of improvement of functional outcomes. CCT is also a learning-based approach and previous studies have shown that successful CCT interventions lead to changes in brain circuitry. It is also known, however, that many cases who are treated with CCT fail to make treatment-related gains. Recent studies have suggested that this may be associated with failures to engage in the training procedures, which could be related to sleep related impairments.
Thus, a broad-spectrum naturalistic comparison of Lurasidone-treated patients with patients treated with other medications is proposed. This would include examining the level of engagement in CCT treatment, measurement of CCT training gains, and relating engagement and training gains with concurrent sleep quality, measured by actigraphy. conditions: Bipolar Disorder conditions: Major Depressive Disorder conditions: Psychosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Lurasidone name: FDA Approved antidepressant treatment measure: Improvement in Cognitive Performance measure: Training Engagement in Cognitive training measure: Nighttime sleep measured with actigraphy sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: George West Mental Health Foundation, DBA Skyland Trail city: Atlanta state: Georgia zip: 30329 country: United States name: Ben W Hunter, MD role: CONTACT phone: 866-504-4966 email: bhunter@skylandtrail.org name: Ben W Hunter, MD role: PRINCIPAL_INVESTIGATOR name: Alex O Rothbaum, PhD, MPH role: SUB_INVESTIGATOR name: Philip D Harvey, PhD role: SUB_INVESTIGATOR lat: 33.749 lon: -84.38798 hasResults: False
nctId: NCT06328127 id: 23-691 briefTitle: Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors acronym: PATH-4 overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-06-30 date: 2029-04-30 date: 2024-03-25 date: 2024-03-25 name: Brigham and Women's Hospital class: OTHER name: Dana-Farber Cancer Institute name: Duke University name: H. Lee Moffitt Cancer Center and Research Institute briefSummary: This randomized clinical trial is evaluating the impact of a positive psychology intervention (PATH) on anxiety symptoms, depression symptoms, and quality of life in survivors of hematopoietic stem cell transplant (HSCT) compared to usual care. conditions: Hematopoietic Stem Cell Transplant studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 400 type: ESTIMATED name: PATH measure: Anxiety Symptoms based on the Hospital Anxiety and Depression Scale-Anxiety Subscale measure: Anxiety Symptoms based on the Hospital Anxiety and Depression Scale-Anxiety Subscale measure: Depression Symptoms based on the Hospital Anxiety and Depression Scale-Depression Subscale measure: Gratitude based on the Gratitude Questionnaire measure: Positive Affect based on the Positive and Negative Affect Schedule Positive Affect Subscale measure: Physical function based on the Patient-Reported Outcomes Measurement Information System-Physical Function-20 measure: Patient-Reported Quality of Life based on the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) measure: Flourishing based on the Flourishing Scale measure: Optimism based on the Life Orientation Test-Revised (LOT-R) measure: Coping based on the Brief-COPE questionnaire measure: Post-traumatic stress based on the Post-traumatic Stress Checklist-Civilian Version measure: Steps per day based on the ActiGraph accelerometer measure: Sedentary leisure time based on the ActiGraph accelerometer sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Moffitt Cancer Center city: Tampa state: Florida zip: 33612 country: United States name: Heather Jim, PhD role: CONTACT email: heather.jim@moffitt.org lat: 27.94752 lon: -82.45843 facility: Dana Farber Cancer Institute city: Boston state: Massachusetts zip: 02215 country: United States lat: 42.35843 lon: -71.05977 facility: Duke Cancer Institute city: Durham state: North Carolina zip: 27710 country: United States name: Thomas LeBlanc, MD role: CONTACT email: thomas.leblanc@duke.edu lat: 35.99403 lon: -78.89862 hasResults: False
nctId: NCT06328114 id: Pro00114549 briefTitle: Accelerating TMS for Cervical Dystonia overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2029-07-01 date: 2029-07-01 date: 2024-03-25 date: 2024-04-26 name: Duke University class: OTHER name: American Academy of Neurology briefSummary: This study aims to investigate the impact of accelerated transcranial magnetic stimulation (TMS) on brain function and behavior in patients with focal cervical dystonia. Previous research demonstrated that individualized TMS improved writing behavior in focal hand dystonia after one session. In this study, we aim to expand the application on TMS on focal cervical dystonia. The current study administers four TMS sessions in a day. The research involves 9 in-person visits. The effect of TMS will be assessed using functional MRI brain scans and behavioral measurements. The risk of TMS includes seizures; the potential risk of seizures from TMS is mitigated through careful screening, adhering to safety guidelines. The study's main benefit is enhancing dystonic behavior and deepening the understanding of brain changes caused by TMS in cervical dystonia, paving the way for further advancements in clinical therapy for this condition. conditions: Isolated Cervical Dystonia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Single-arm crossover study design with subjects receiving TMS at two different intensities primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: The TMS intensity delivered at each TMS visit will be masked whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Transcranial Magnetic Stimulation (TMS) measure: Change in Neck Angles as Measured by Neck Sensor Device measure: Changes in Brain Activity (bold activity) on Functional Magnetic Resonance Imaging (fMRI) measure: Changes in Brain Activity (functional connectivity) on Functional Magnetic Resonance Imaging (fMRI) measure: Behavioral Response After Deep Brain Stimulation (DBS), as measured by Neck Angles sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Duke University Health System city: Durham state: North Carolina zip: 27705 country: United States name: Noreen Bukhari-Parlakturk, MD PhD role: CONTACT phone: 919-668-8248 email: movdisres@duke.edu lat: 35.99403 lon: -78.89862 hasResults: False
nctId: NCT06328101 id: 2023-02558 briefTitle: Autoimmune Pancreatitis, Pancreatic and Extrapancreatic cAnceR (AiPPEAR) acronym: AiPPEAR overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-09-01 date: 2025-04-01 date: 2024-03-25 date: 2024-03-25 name: University Medical Center Goettingen class: OTHER name: University Medical Centre Maribor name: Aalborg University Hospital name: University Hospital Munich name: Tartu University Hospital name: University Hospital in Halle briefSummary: The goal of this observational, retrospective study is to learn about cancer risk in autoimmune pancreatitis (AIP) patients. The main questions it aims to answer are:
* What are the characteristics of AIP patients associated with the incidence of cancer? conditions: Autoimmune Pancreatitis Type 1 conditions: Autoimmune Pancreatitis Type 2 studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1000 type: ESTIMATED measure: Standardized incidence ratio (SIR) of first invasive cancer measure: The prevalence of cancer diagnoses 12 months prior to AIP diagnosis measure: Risk factor associated with cancer diagnosis. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False